Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-adjuvanted trivalent subunit influenza vaccine
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A non-adjuvanted trivalent subunit influenza vaccine is an inactivated (killed virus) flu vaccine formulation containing purified surface antigens (hemagglutinin and neuraminidase) from three different strains of the influenza virus—typically two A strains and one B strain. Unlike adjuvanted vaccines, it does not contain any immune-boosting additives. The "subunit" designation means only specific viral proteins are included, reducing reactogenicity compared to whole-virus or split-virus vaccines. These vaccines are administered intramuscularly and are designed to induce protective antibody responses against circulating seasonal flu viruses. They are widely used for annual immunization of adults and children as a standard option when adjuvanted or high-dose formulations are not indicated or available[3][4].
- Brand names
- AgrippalBegripalInfluvacFluvirinSandovac
- Other names
- trivalent inactivated influenza vaccine non-adjuvantedTIV non-adjuvantedstandard-dose trivalent subunit influenza vaccine
02
Targets
HA stem (Influenza A hemagglutinin stem region)HA (Hemagglutinin)
Beyond the preview
Go deeper on non-adjuvanted trivalent subunit influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-adjuvanted trivalent subunit influenza vaccine.